MX2024008474A - Compuestos y metodos para tratar la ataxia de friedreich. - Google Patents

Compuestos y metodos para tratar la ataxia de friedreich.

Info

Publication number
MX2024008474A
MX2024008474A MX2024008474A MX2024008474A MX2024008474A MX 2024008474 A MX2024008474 A MX 2024008474A MX 2024008474 A MX2024008474 A MX 2024008474A MX 2024008474 A MX2024008474 A MX 2024008474A MX 2024008474 A MX2024008474 A MX 2024008474A
Authority
MX
Mexico
Prior art keywords
terminus
compounds
methods
binding
ataxia
Prior art date
Application number
MX2024008474A
Other languages
English (en)
Spanish (es)
Inventor
Chengzhi Zhang
Pratik Shah
Sean Jeffries
Aseem Ansari
Abhijit Bhat
Original Assignee
Design Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Design Therapeutics Inc filed Critical Design Therapeutics Inc
Publication of MX2024008474A publication Critical patent/MX2024008474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2024008474A 2022-01-06 2023-01-06 Compuestos y metodos para tratar la ataxia de friedreich. MX2024008474A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263297090P 2022-01-06 2022-01-06
US202263382854P 2022-11-08 2022-11-08
PCT/US2023/010331 WO2023133284A2 (en) 2022-01-06 2023-01-06 Compounds and methods for treating friedreich's ataxia

Publications (1)

Publication Number Publication Date
MX2024008474A true MX2024008474A (es) 2024-07-12

Family

ID=87074158

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008474A MX2024008474A (es) 2022-01-06 2023-01-06 Compuestos y metodos para tratar la ataxia de friedreich.

Country Status (14)

Country Link
US (1) US20250109132A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460302A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025502064A (cg-RX-API-DMAC7.html)
KR (1) KR20240138079A (cg-RX-API-DMAC7.html)
AU (1) AU2023205889A1 (cg-RX-API-DMAC7.html)
CA (1) CA3246468A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002029A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024010651A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240321A (cg-RX-API-DMAC7.html)
IL (1) IL314006A (cg-RX-API-DMAC7.html)
MX (1) MX2024008474A (cg-RX-API-DMAC7.html)
PE (1) PE20241730A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334148A (cg-RX-API-DMAC7.html)
WO (1) WO2023133284A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116490507A (zh) 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2025076181A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
EP4788669A1 (en) * 2023-10-03 2026-08-12 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease
WO2025076219A1 (en) * 2023-10-03 2025-04-10 Design Therapeutics, Inc. Methods and compounds for modulating huntington's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2015053413A1 (ja) * 2013-10-11 2015-04-16 千葉県 ドライバーオンコジーンの遺伝子変異を標的にアルキル化する新規アルキル化剤
US11759533B2 (en) * 2017-03-29 2023-09-19 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
WO2020253711A1 (zh) * 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
JP7465945B2 (ja) * 2019-07-02 2024-04-11 ニューベイション・バイオ・インコーポレイテッド Bet阻害剤としてのヘテロ環式化合物
CA3204523A1 (en) * 2021-01-08 2022-07-14 Aseem Ansari Methods and compounds for treating friedreich's ataxia

Also Published As

Publication number Publication date
IL314006A (en) 2024-08-01
CR20240321A (es) 2024-10-16
AU2023205889A1 (en) 2024-08-15
CO2024010651A2 (es) 2024-08-08
EP4460302A2 (en) 2024-11-13
US20250109132A1 (en) 2025-04-03
CA3246468A1 (en) 2023-07-13
EP4460302A4 (en) 2025-12-24
WO2023133284A3 (en) 2023-08-24
WO2023133284A2 (en) 2023-07-13
KR20240138079A (ko) 2024-09-20
PE20241730A1 (es) 2024-08-19
CL2024002029A1 (es) 2024-11-04
TW202334148A (zh) 2023-09-01
JP2025502064A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
WO2023133284A3 (en) Compounds and methods for treating friedreich's ataxia
EP4234553A3 (en) Methods and compounds for the treatment of genetic disease
MX2023008153A (es) Metodos y compuestos para tratar la ataxia de friedreich.
EP4234550A3 (en) Methods and compounds for the treatment of genetic disease
ATE544473T1 (de) Chimäre moleküle zur modulation der genexpression
CY1119614T1 (el) ΟΛΙΓΟΜΕΡΕΙΣ ΕΝΩΣΕΙΣ ΓΙΑ ΤΗ ΔΙΑΜΟΡΦΩΣΗ ΤΗΣ ΕΚΦΡΑΣΗΣ HIF-1α
Collins et al. In situ conjugation of dithiophenol maleimide polymers and oxytocin for stable and reversible polymer–peptide conjugates
NO20031687L (no) Veksthormonsekretagoger
JP2010505897A5 (cg-RX-API-DMAC7.html)
AU2003202585A1 (en) Disubstituted thiazolyl carboxanilides and their use as microbicides
DE69333815D1 (de) Gentranskription und ionisierende strahlung: methoden und zusammensetzungen
Hong et al. Efficient synthesis and biological activity of Psammaplin A and its analogues as antitumor agents
MX2008011038A (es) Plantas que tienen un rendimiento incrementado y metodo para obtenerlas.
MX2025006068A (es) Proteina de union cldn18.2/4-1bb y su uso medico
WO2023283403A3 (en) Bis-rnai compounds for cns delivery
WO2023192642A3 (en) Methods and compounds for modulating huntington's disease
BR0313455A (pt) modulação "antisense" da expressão de nav1.3
WO2007121326A3 (en) Compositions and methods for modulating gene expression
MX2023013078A (es) Anticuerpos de inmunorreceptor de celulas t con dominios ig e itim (anti-tigit), anticuerpos de cumulo de diferenciacion 96 (anti-cd96) y metodos de uso de estos.
ATE439856T1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
AR121257A1 (es) Métodos y compuestos para el tratamiento de enfermedad genética
RU2009108640A (ru) Лекарственные средства, усиливающие репарацию спинно-мозговых нервов, содержащие в качестве активного ингредиента дезацилгрелин или его производные
AR128224A1 (es) Compuestos y métodos para tratar la ataxia de friedreich
WO2021011377A3 (en) Methods of enhancing immunogenicity of cancers
ATE309265T1 (de) Peptidverbindung, die von einem verschobenen offenen leserahmen des ice-gens abstammt